profit from every $100 of sales.
$0$100
Alvotech
$4.19-10.28% today
-18.0% in 1 year
1-year low $3.001-year high $6.15
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $53.55 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Alvotech sold, what it kept, and what it did with the cash.
Sales went from $83.0 million in 2022 to $586 million in 2025, with $27.9 million of profit last year.
SalesProfit
Alvotech vs. similar companies
Alvotech grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alvotech | 53.6× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Alvotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 83 | 91 | 490 | 586 | |
| 19 | -69 | 304 | 351 | |
| -346 | -355 | 70 | 78 | |
| -454 | -494 | -32 | 311 | |
| -514 | -552 | -232 | 28 | |
| -2.60 | -2.43 | -0.87 | 0.10 | |
| 22.8% | -75.9% | 62.2% | 59.8% | |
| -417.3% | -388.1% | 14.2% | 13.3% | |
| -618.6% | -603.4% | -47.3% | 4.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 828 | 950 | 1,221 | 1,487 |
| Cash | 66 | 11 | 51 | 172 |
| Total debt | 805 | 1,075 | 1,190 | 1,449 |
| Total liabilities | 1,393 | 1,883 | 1,634 | 1,772 |
| -564 | -932 | -413 | -284 | |
| 198 | 268 | 267 | 279 | |
| -155.6% | -286.1% | -6.5% | 18.5% | |
| 91.0% | 59.2% | 56.2% | -9.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -312 | -312 | -237 | -50 | |
| 49 | 46 | 57 | 96 | |
| -361 | -359 | -294 | -146 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 18 | 8 | 7 |
Valuation
- 53.6×
- 161.5×
- –
- -3.2×
- 2.5×
- –
- 8.9×
- -9.8%
- 1.9%
- 0.0%
Profitability
- 59.8%
- 13.3%
- 4.8%
- 13.3%
- 1.3%
- -130.6%
- -11.9%
- 1.9%
- 6.6%
- 31.4%
Growth
- +91.9%
- –
- +61.0%
- –
- +72.9%
Financial health
- 16.3×
- -5.09
- 97.4%
- 0.5×
- 1.89
- 1.16
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 964
Top 44%of 898
Bottom 20%of 651
Top 5%of 911
Bottom 9%of 991
What analysts expect
- Average price target
- $8.33
- Range
- $5.00 – $10.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.09 | -0.07 | −28.6% |
| Mar 18, 2026 | -0.37 | -0.01 | −6,334.8% |
| Nov 12, 2025 | -0.02 | 0.05 | −140.0% |
| Aug 13, 2025 | 0.14 | -0.26 | +153.8% |
| May 7, 2025 | 0.35 | -0.17 | +305.9% |
| Mar 26, 2025 | -0.24 | -0.39 | +38.5% |
| Nov 13, 2024 | 0.19 | -0.06 | +401.6% |
| Aug 15, 2024 | 0.28 | -0.28 | +200.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
15No pass
Philip Fisher
33No pass
Peter Lynch
76Pass
Joel Greenblatt
34No pass
Charlie Munger
24No pass
Terry Smith
27No pass
Questions about Alvotech
Is Alvotech a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alvotech AI analysis
What does Alvotech do?
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. It is in Drug Manufacturers - Specialty & Generic.
Does Alvotech pay a dividend?
No. Alvotech does not pay a dividend at the moment.
Is Alvotech stock halal?
No. Alvotech does not pass our halal screen: its debt is 97% of its market value, at or above the 33% limit. How we check
How has Alvotech stock done over the past year?
Down 18.0% over the past twelve months, to $4.19. It traded between $3.00 and $6.15 and is 31.9% below its high.
Who are Alvotech's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Alvotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.